Pathos AI, Inc.

Based in Chicago, US, and founded in 2022 by CEO Ryan Fukushima, Pathos AI, Inc. operates as a provider of an AI-driven biotechnology platform that offers advanced drug development services to pharmaceutical companies looking for advanced treatment pathways. In October 2024, Pathos AI, Inc. raised USD 62 million in Series C funding led by New Enterprise Associates, with participation from Revolution Ventures, Lightbank, and Builders VC.

Pathos AI, Inc. specializes in advancing drug development through its proprietary PathOS Platform, which integrates real-world oncology data and patient-derived functional genomic data. This platform enables the identification and validation of biological targets that traditional methods may overlook, ultimately focused on developing precision medicines. By partnering with biopharmaceutical companies.

Their solutions cater primarily to oncology-focused pharmaceutical and biotechnology firms across various geographical markets, including North America, Europe, and select regions in Asia. Pathos AI, Inc. generates revenue primarily through strategic partnerships and licensing agreements with biopharmaceutical companies, where they co-develop and license clinical-stage therapeutics. The transaction structure encompasses B2B relationships wherein drug companies collaborate with Pathos to leverage its AI-driven insights for drug development.

Pathos AI, Inc. is working on new product developments aimed at improving its PathOS Platform capabilities, with specific launches anticipated in the next 18 months. The company plans to expand its reach into European and Asian markets by 2025, focusing on collaborations with local biopharmaceutical firms.